Fundraising FoxBain Capital Life Sciences — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Longeviti Neuro Solutions develops cranial implant platforms for complex brain surgery, including patient-specific and off-the-shelf implants that restore skull contour and enable real-time post-operative ultrasound imaging.
HealthtechMedical Devices
Jesse Christopher(CEO & Co-founder)in
Co-investorsMaryland TEDCOTEDCO
Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US
Sri Kosuri(Founder)inRamsey Homsany(Founder)inRobert Andrade(Executive Officer, Director, Promoter)Maurice J. Costantini(Executive Officer, Director, Promoter)
Co-investorsAndreessen Horowitz+ND Capital8VCCarbon SiliconCatalio Capital Management, LPExplorer Investments+10 more
Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics.
BiotechDigital HealthHealthtechMedical DevicesNatick, US
Shawn Liu(Director)Hui Yang(Director)Gang Song(Executive Officer, Director)Zhaohui Wang(Director)Robert Forrester(Director)inHong Fang Song(Director)
Co-investorsCatalio Capital Management, LPHB VenturesSoleus Capital
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.
BiotechHealthtechMental Health
Co-investorsThird Rock VenturesGV (Google Ventures)
Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.
BiotechMedical Devices
Tony Estrada(President & Chief Executive Officer; co-founder)in
Co-investorsARCH Venture PartnersF-Prime CapitalDigitalis VenturesForbionMubadala Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.